

# Shereen M Shehata

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3085368/publications.pdf>

Version: 2024-02-01

14  
papers

158  
citations

1162367

8  
h-index

1125271

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

134  
citing authors

#	ARTICLE	IF	CITATIONS
1	Silver nanoparticles biosynthesis using <i>Saussurea costus</i> root aqueous extract and catalytic degradation efficacy of safranin dye. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 1093-1099.	1.8	20
2	Molecular profile of aflatoxigenic and non-aflatoxigenic isolates of <i>Aspergillus flavus</i> isolated from stored maize. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 1383-1391.	1.8	10
3	Evaluation of crude oil biodegradation using mixed fungal cultures. <i>PLoS ONE</i> , 2021, 16, e0256376.	1.1	9
4	Development and validation of UPLC-MS/MS method for the simultaneous quantification of anaplastic lymphoma kinase inhibitors, alectinib, ceritinib, and crizotinib in Wistar rat plasma with application to bromelain-induced pharmacokinetic interaction. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 204, 114276.	1.4	9
5	Development and validation of UPLC-MS/MS method for studying the pharmacokinetic interaction of dasabuvir and tamoxifen, 4-hydroxytamoxifen in Wistar rats. <i>Scientific Reports</i> , 2020, 10, 3521.	1.6	5
6	Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats. <i>PeerJ</i> , 2020, 8, e9881.	0.9	8
7	UPLC-MS/MS study of the effect of dandelion root extract on the plasma levels of the selected irreversible tyrosine kinase inhibitors dasatinib, imatinib and nilotinib in rats: Potential risk of pharmacokinetic interactions. <i>Biomedical Chromatography</i> , 2019, 33, e4674.	0.8	10
8	A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction. <i>BioMed Research International</i> , 2019, 2019, 1-13.	0.9	0
9	Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats. <i>PLoS ONE</i> , 2018, 13, e0199208.	1.1	11
10	Ultra-performance LC-MS/MS study of the pharmacokinetic interaction of imatinib with selected vitamin preparations in rats. <i>Bioanalysis</i> , 2018, 10, 1099-1113.	0.6	6
11	UPLC-ESI-MS/MS study of the effect of green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: Potential risk of pharmacokinetic interaction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1049-1050, 30-40.	1.2	21
12	Comparative pharmacokinetic profiles of selected irreversible tyrosine kinase inhibitors, neratinib and pelitinib, with apigenin in rat plasma by UPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 137, 258-267.	1.4	18
13	Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1028, 100-110.	1.2	12
14	Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 124, 216-227.	1.4	19